These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 24142574)

  • 41. Amplification of HSD17B1 and ERBB2 in primary breast cancer.
    Gunnarsson C; Ahnström M; Kirschner K; Olsson B; Nordenskjöld B; Rutqvist LE; Skoog L; Stål O
    Oncogene; 2003 Jan; 22(1):34-40. PubMed ID: 12527905
    [TBL] [Abstract][Full Text] [Related]  

  • 42. miR-155 downregulates ErbB2 and suppresses ErbB2-induced malignant transformation of breast epithelial cells.
    He XH; Zhu W; Yuan P; Jiang S; Li D; Zhang HW; Liu MF
    Oncogene; 2016 Nov; 35(46):6015-6025. PubMed ID: 27065318
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Relationship between five GWAS-identified single nucleotide polymorphisms and female breast cancer in the Chinese Han population.
    He Y; Liu H; Chen Q; Sun X; Liu C; Shao Y
    Tumour Biol; 2016 Jul; 37(7):9739-44. PubMed ID: 26803517
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
    Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
    Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association of ErbB1-4 expression in invasive breast cancer with clinicopathological characteristics and prognosis.
    Fujiwara S; Ibusuki M; Yamamoto S; Yamamoto Y; Iwase H
    Breast Cancer; 2014 Jul; 21(4):472-81. PubMed ID: 23100016
    [TBL] [Abstract][Full Text] [Related]  

  • 46. GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patients.
    Cox DG; Curtit E; Romieu G; Fumoleau P; Rios M; Bonnefoi H; Bachelot T; Soulié P; Jouannaud C; Bourgeois H; Petit T; Tennevet I; Assouline D; Mathieu MC; Jacquin JP; Lavau-Denes S; Darut-Jouve A; Ferrero JM; Tarpin C; Lévy C; Delecroix V; Trillet-Lenoir V; Cojocarasu O; Meunier J; Pierga JY; Faure-Mercier C; Blanché H; Sahbatou M; Boland A; Bacq D; Besse C; Deleuze JF; Pauporté I; Thomas G; Pivot X
    Oncotarget; 2016 Nov; 7(47):77358-77364. PubMed ID: 27764800
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MiR-34a modulates ErbB2 in breast cancer.
    Wang Y; Zhang X; Chao Z; Kung HF; Lin MC; Dress A; Wardle F; Jiang BH; Lai L
    Cell Biol Int; 2017 Jan; 41(1):93-101. PubMed ID: 27813227
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Elucidating the genomic landscape of breast cancer: how will this affect treatment?
    Stjepanovic N; Bedard PL
    Pharmacogenomics; 2015; 16(6):569-72. PubMed ID: 25893859
    [No Abstract]   [Full Text] [Related]  

  • 49. Relative quantification of ERBB2 mRNA in invasive duct carcinoma of the breast: correlation with ERBB-2 protein expression and ERBB2 gene copy number.
    Mrhalová M; Kodet R; Kalinová M; Hilská I
    Pathol Res Pract; 2003; 199(7):453-61. PubMed ID: 14521261
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A negative feedback regulatory loop associates the tyrosine kinase receptor ERBB2 and the transcription factor GATA4 in breast cancer cells.
    Hua G; Zhu B; Rosa F; Deblon N; Adélaïde J; Kahn-Perlès B; Birnbaum D; Imbert J
    Mol Cancer Res; 2009 Mar; 7(3):402-14. PubMed ID: 19276186
    [TBL] [Abstract][Full Text] [Related]  

  • 51. ErbB2 transgenic mice: a tool for investigation of the immune prevention and treatment of mammary carcinomas.
    Quaglino E; Mastini C; Forni G; Cavallo F
    Curr Protoc Immunol; 2008 Aug; Chapter 20():Unit 20.9.1-20.9-10. PubMed ID: 18729063
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
    Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
    Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
    [TBL] [Abstract][Full Text] [Related]  

  • 53. c-erbB2 and topoisomerase IIalpha protein expression independently predict poor survival in primary human breast cancer: a retrospective study.
    Fritz P; Cabrera CM; Dippon J; Gerteis A; Simon W; Aulitzky WE; van der Kuip H
    Breast Cancer Res; 2005; 7(3):R374-84. PubMed ID: 15987433
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Flotillins as regulators of ErbB2 levels in breast cancer.
    Pust S; Klokk TI; Musa N; Jenstad M; Risberg B; Erikstein B; Tcatchoff L; Liestøl K; Danielsen HE; van Deurs B; Sandvig K
    Oncogene; 2013 Jul; 32(29):3443-51. PubMed ID: 22869152
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Grb2 downregulation leads to Akt inactivation in heregulin-stimulated and ErbB2-overexpressing breast cancer cells.
    Lim SJ; Lopez-Berestein G; Hung MC; Lupu R; Tari AM
    Oncogene; 2000 Dec; 19(54):6271-6. PubMed ID: 11175341
    [TBL] [Abstract][Full Text] [Related]  

  • 56. ErbB2 down-regulates microRNA-205 in breast cancer.
    Adachi R; Horiuchi S; Sakurazawa Y; Hasegawa T; Sato K; Sakamaki T
    Biochem Biophys Res Commun; 2011 Aug; 411(4):804-8. PubMed ID: 21787752
    [TBL] [Abstract][Full Text] [Related]  

  • 57. First Therapy Targeting ERBB2-Low Breast Cancer Approved.
    Larkin HD
    JAMA; 2022 Sep; 328(9):819. PubMed ID: 36066537
    [No Abstract]   [Full Text] [Related]  

  • 58. Genetic screening could improve breast cancer prevention, study finds.
    Kmietowicz Z
    BMJ; 2015 Apr; 350():h1879. PubMed ID: 25858913
    [No Abstract]   [Full Text] [Related]  

  • 59. Meta-analyses of etiologic studies should account for the underlying biologic mechanisms.
    Neilson HK
    Breast Cancer Res Treat; 2015 Feb; 149(3):799-800. PubMed ID: 25656680
    [No Abstract]   [Full Text] [Related]  

  • 60. Polymorphisms of ERBB2 and breast cancer risk: a meta-analysis of 26 studies involving 35,088 subjects.
    Kadlubar SA
    J Surg Oncol; 2013 Nov; 108(6):335-6. PubMed ID: 24142574
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.